Journal article
Characterization of the selective indoleamine 2,3-dioxygenase-1 (IDO1) catalytic inhibitor EOS200271/PF-06840003 supports IDO1 as a critical resistance mechanism to PD-(L)1 blockade therapy
- Abstract:
-
Tumors use Indoleamine 2,3-dioxygenase-1 (IDO1) as a major mechanism to induce an immunosuppressive microenvironment. IDO1 expression is upregulated in many cancers and considered to be a resistance mechanism to immune checkpoint therapies. IDO1 is induced in response to inflammatory stimuli such as IFN and promotes immune tolerance by depleting tryptophan and producing tryptophan catabolites including kynurenine in the tumor microenvironment. This leads to effector T-cell anergy and enhance...
Expand abstract
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Accepted manuscript, pdf, 3.2MB)
-
- Publisher copy:
- 10.1158/1535-7163.mct-17-1104
Why is the content I wish to access not available via ORA?
Bibliographic data (the information relating to research outputs) and full-text items (e.g. articles, theses, reports, etc.) arrive in ORA from several different sources. Unfortunately we are not able to make available the full-text for every research output.
Please contact the ORA team (
) if you have queries regarding unavailable content OR if you are aware of a full-text copy we can make available.
) if you have queries regarding unavailable content OR if you are aware of a full-text copy we can make available.
Content may be unavailable for the following four reasons
-
Version unsuitable
-
We have not obtained a suitable full-text for a given research output. See this page for more information.
-
Recently completed
-
Sometimes content is held in ORA but is unavailable for a fixed period of time to comply with the policies and wishes of rights holders.
-
Permissions
-
All content made available in ORA should comply with relevant rights, such as copyright. See this page for more information.
-
Clearance
-
Some thesis volumes scanned as part of the digitisation scheme funded by Dr Leonard Polonsky are currently unavailable due to sensitive material or uncleared third-party copyright content. We are attempting to contact authors whose theses are affected.
Alternative access to the full-text
You may be able to access the full-text directly from the publisher's website using the 'Publisher Copy' link in the 'Links & Downloads' box from a research output's ORA record page. This method may require an institutional or individual subscription to the journal/resource.
Authors
Bibliographic Details
- Publisher:
- American Association for Cancer Research Publisher's website
- Journal:
- Molecular cancer therapeutics Journal website
- Volume:
- 17
- Issue:
- 12
- Pages:
- 2530-2542
- Publication date:
- 2018-09-19
- Acceptance date:
- 2018-09-12
- DOI:
- ISSN:
-
1535-7163 and 1538-8514
- Pmid:
-
30232146
- Source identifiers:
-
921624
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:921624
- UUID:
-
uuid:0d4fbf62-5a29-4242-9a49-40407c657439
- Local pid:
- pubs:921624
- Deposit date:
- 2018-10-03
Terms of use
- Copyright holder:
- American Association for Cancer Research
- Copyright date:
- 2018
- Notes:
- ©2018, American Association for Cancer Research. This is the accepted manuscript version of the article. The final version is available online from American Association for Cancer Research at: 10.1158/1535-7163.mct-17-1104
If you are the owner of this record, you can report an update to it here: Report update to this record